Changes in use of antiretroviral therapy in regions of Europe over time

被引:48
作者
Kirk, O [1 ]
Mocroft, A
Katzenstein, TL
Lazzarin, A
Antunes, F
Francioli, P
Brettle, RP
Parkin, JM
Gonzales-Lahoz, J
Lundgren, JD
机构
[1] Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis 144, Coordinating Ctr EuroSIDA, DK-2650 Hvidovre, Denmark
[2] Royal Free Hosp, London NW3 2QG, England
[3] Rigshosp, DK-2100 Copenhagen, Denmark
[4] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy
[5] Hosp Santa Maria, Lisbon, Portugal
[6] CHU Vaudois, CH-1011 Lausanne, Switzerland
[7] City Hosp, Edinburgh, Midlothian, Scotland
[8] St Bartholomews Hosp, London, England
[9] Hosp Del Rey, Madrid, Spain
关键词
HIV infection; combination therapy; components of combination therapy; protease inhibitor; regional differences in Europe;
D O I
10.1097/00002030-199815000-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To analyse use of antiretroviral therapy within Europe between 1994 and 1997. Design: From September 1994, the EuroSIDA study (cohorts I-III) has prospectively followed unselected HIV-infected patients from 50 clinical centres in 17 European countries (total, 7230). Methods: Patients under follow-up at half-year intervals from September 1994 (n = 2871) to September 1997 (n = 3682) were classified according to number of drugs currently used (none, one, two, three, four or more). Use of antiretroviral therapy was stratified by CD4 cell count (< 200 versus greater than or equal to 200 x 10(6)/l) and by region of Europe (south, central, or north). Frequency data were compared by chi(2) test and logistic regression modelling. Results: The proportion of patients on antiretroviral monotherapy diminished over time (1994, 42%; 1997, 3%), as did the proportion of patients without therapy (from 97 to 9%). Over time, the proportion of patients on triple (from 2 to 55%) and quadruple (from 0 to 9%) therapy increased, whereas use of dual therapy peaked in 1996 and subsequently fell. In the three regions of Europe, changes in use of antiretroviral therapy differed substantially. However, as of September 1997, only minor differences persisted. The proportion of patients on dual, triple, and quadruple therapy were as follow. south, 33, 52 and 5%, respectively; central, 23, 55 and 14%, respectively; north, 16, 59 and 10%, respectively. In September 1997, odds for use of three or more drugs including at least one protease inhibitor did not differ significantly between regions. Conclusions: Use of antiretroviral therapy in Europe has changed dramatically towards combination treatment in the last few years. Regional differences in use of antiretroviral therapy have decreased, and by September 1997 only minor differences remained. Antiretroviral therapy with three or more drugs and use of protease inhibitors has become more common in all regions of Europe. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:2031 / 2039
页数:9
相关论文
共 23 条
  • [1] Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
  • [2] Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
    Cameron, DW
    Heath-Chiozzi, M
    Danner, S
    Cohen, C
    Kravcik, S
    Maurath, C
    Sun, E
    Henry, D
    Rode, R
    Potthoff, A
    Leonard, J
    [J]. LANCET, 1998, 351 (9102) : 543 - 549
  • [3] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1962 - 1969
  • [4] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [5] COHEN C, 1996, 36 INT C ANT AG CHEM
  • [6] COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION
    COLLIER, AC
    COOMBS, RW
    FISCHL, MA
    SKOLNIK, PR
    NORTHFELT, D
    BOUTIN, P
    HOOPER, CJ
    KAPLAN, LD
    VOLBERDING, PA
    DAVIS, LG
    HENRARD, DR
    WELLER, S
    COREY, L
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) : 786 - 793
  • [7] Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3
  • [8] THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISCHL, MA
    RICHMAN, DD
    HANSEN, N
    COLLIER, AC
    CAREY, JT
    PARA, MF
    HARDY, WD
    DOLIN, R
    POWDERLY, WG
    ALLAN, JD
    WONG, B
    MERIGAN, TC
    MCAULIFFE, VJ
    HYSLOP, NE
    RHAME, FS
    BALFOUR, HH
    SPECTOR, SA
    VOLBERDING, P
    PETTINELLI, C
    ANDERSON, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) : 727 - 737
  • [9] THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    FISCHL, MA
    RICHMAN, DD
    GRIECO, MH
    GOTTLIEB, MS
    VOLBERDING, PA
    LASKIN, OL
    LEEDOM, JM
    GROOPMAN, JE
    MILDVAN, D
    SCHOOLEY, RT
    JACKSON, GG
    DURACK, DT
    KING, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) : 185 - 191
  • [10] British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
    Gazzard, BG
    Moyle, GJ
    Weber, J
    Johnson, M
    Bingham, JS
    Brettle, R
    Churchill, D
    Fisher, M
    Griffin, G
    Jefferies, D
    King, E
    Gormer, R
    Lee, C
    Pozniak, A
    Smith, JR
    TudorWilliams, G
    Williams, I
    [J]. LANCET, 1997, 349 (9058) : 1086 - 1092